The effects of administered disease-modifying treatments in MS to the gut microbiome

In recent years, more and more papers have appeared in the literature to study the role of the microbiota in the development of various pathological processes in the central nervous system (CNS), including the development of the pathological process in multiple sclerosis (MS), through the brain-gut axis. In this regard, the question of the effect of administered disease-modifying treatments in MS on the composition of the microbiota is interesting. The purpose of this review article is to summarize the current evidence investigating the effect of administered disease-modifying treatments in MS on the gut microbiome.